Kim et al. [145] have provided evidence that CD33 depletion from normal hematopoietic stem and progenitor cells (HSPC) prior to autologous HSPC transplantation can generate a functional hematopoietic system that allows specific targeting of AML using CD33-directed CAR-T cells. This evidence concerns the gene CD33 and acute myeloid leukemia.